Core Points - Liu Zhonghua, the Vice President of Shuoshi Biotechnology, passed away due to sudden illness on September 12, 2025, at the age of 56 [2] - Liu was a core founder of the company and made significant contributions to its establishment and growth, particularly in the fields of infectious disease testing, cancer screening, and maternal and child health diagnostics [4][5] - Liu held a Ph.D. from Xi'an Jiaotong University and was an expert in molecular biology, with a career that included research at the Chinese Academy of Medical Sciences and collaborations in the U.S. [4] - Following Liu's death, the board of directors of Shuoshi Biotechnology decreased from 9 to 8 members, which does not affect the normal operation of the board but is below the number stipulated in the company's articles of association [5]

Core Points - The company announced the passing of its Vice President Liu Zhonghua due to sudden illness on September 12, 2025, at the age of 56 [1] - Liu Zhonghua was a molecular biology expert in China, with a focus on virology and molecular biology research [1] - He had previously worked at the Chinese Academy of Medical Sciences and conducted collaborative research in the United States from 2008 to 2009 before joining the company in 2010 [1]

证券代码：688399 证券简称：硕世生物 公告编号：2025-033 江苏硕世生物科技股份有限公司 关于公司董事、副总经理逝世的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）沉痛公告，公司董事、 副总经理刘中华先生因突发疾病于 2025 年 9 月 12 日晨不幸逝世。公司及全体员 工对此表示深切的哀悼，并向其家属致以诚挚的慰问。 江苏硕世生物科技股份有限公司 董事会 2025 年 9 月 13 日 刘中华先生始终秉持实业报国的信念，积极践行社会责任，将毕生心力奉献 于传染病检测、肿瘤筛查及妇幼健康相关诊断产品的研发事业。他曾荣获江苏省 优秀共产党员、江苏省新冠肺炎疫情防控先进个人、全国劳动模范等多项荣誉。 作为公司核心创始人之一，他多年恪尽职守、勤勉奉献，为公司的创立与成长作 出了不可磨灭的贡献。在担任公司董事及副总经理期间，他勤勉务实、履职尽责， 对公司发展起到了重要的推动作用。公司及全体员工谨向刘中华先生致以崇高敬 意和衷心感谢。 截至本公告披露日，刘中华先生直接 ...

Company Overview - Jiangsu Shuoshi Biological Technology Co., Ltd. is located at 837 Yaochedada, Taizhou, Jiangsu Province, established on April 12, 2010, and listed on December 5, 2019. The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments [1] - The main business revenue composition includes: testing reagents 85.89%, purchased instruments and materials 7.19%, testing instruments 3.84%, testing services 2.24%, and others 0.84% [1] Stock Performance - On September 12, Shuoshi Biological's stock rose by 5.1%, reaching a price of 65.98 yuan per share, with a trading volume of 124 million yuan and a turnover rate of 2.29%. The total market capitalization is 5.534 billion yuan [1] Shareholder Information - Among the top ten circulating shareholders of Shuoshi Biological, one fund from Huaxia Fund holds a significant position. Huaxia Industry Prosperity Mixed Fund (003567) increased its holdings by 1.0079 million shares in the second quarter, totaling 2.2546 million shares, which accounts for 2.69% of the circulating shares. The estimated floating profit today is approximately 7.2148 million yuan [2] - Huaxia Industry Prosperity Mixed Fund (003567) was established on February 4, 2017, with a latest scale of 7.261 billion yuan. Year-to-date returns are 49.16%, ranking 881 out of 8174 in its category; the one-year return is 99.56%, ranking 463 out of 7981; and since inception, the return is 357.78% [2]

Core Viewpoint - The IVD industry is facing significant challenges, leading to salary reductions among executives and a general downturn in performance across the sector [2][4][7]. Company Summary - The company, Shuoshi Biological, has announced voluntary salary reductions for its executives due to ongoing economic and industry challenges, aiming to optimize operational costs and enhance management efficiency [2]. - The core executive team's salaries will be significantly reduced starting August 15, 2025, with the chairman's and general manager's salaries cut by 50% [4]. - The company's revenue for the first half of 2025 was 176 million yuan, a slight decrease of 1.05% year-on-year, while net profit dropped by 86.35% to 3.99 million yuan [4][5]. - The company experienced explosive growth during the pandemic, with revenue peaking at 5.535 billion yuan in 2022, but has since declined to 403 million yuan in 2023 and is projected to fall further to 349 million yuan in 2024 [4][5]. Industry Summary - The IVD industry has entered a downward cycle since peaking in 2022, with over 40 out of 60 publicly listed companies reporting declines in both revenue and net profit in the first half of 2025 [7]. - Price pressures from centralized procurement have significantly impacted profit margins, with average price reductions of 77% to 92% reported in certain regions [7]. - The implementation of mutual recognition of test results among medical institutions has reduced the demand for repeated testing, further decreasing the consumption of testing reagents [7]. - The company is exploring overseas markets as a potential solution to domestic challenges, with plans to establish international marketing teams and diversify sales channels [8]. - Despite a 31.32% year-on-year increase in overseas revenue to 693,420 yuan, it still represents only 3.95% of total revenue [8].

（原标题：硕世生物董监高降薪，IVD行业寒意下寻求纾困之道） 21世纪经济报道记者 唐唯珂 广州报道 初秋的IVD行业已经开始寒意四伏。 此前，硕世生物发布公告称，部分董事、监事及全体高管主动提交《关于自愿降薪的函》。 公告显示，当前，全球经济形势及行业环境面临诸多挑战，为进一步支持公司优化运营成本、提升管理 效率、增强持续竞争力，实现稳健发展战略目标，上述人员基于对公司未来发展的坚定信心及共同担 当，自愿提出调整薪酬。 公开资料显示，硕世生物成立于2010年，专注于体外诊断（IVD）领域，主营业务覆盖试剂、配套检测 仪器以及体外检测服务，形成"试剂+仪器+服务"的一体化模式，客户涵盖疾控机构、医院、第三方检 测机构及科研单位。 另有IVD从业者向21世纪经济报道记者直言，业内已有其他抗体龙头企业开始裁员，行业仍在阵痛期。 此外值得注意的是，9月4日，万孚审计监察部通过公众号发布消息，为鼓励员工积极举报违规行为、共 同维护公司利益，由该部门制定的《举报奖励实施细则》即日起正式生效。值得关注的是，此次举报奖 励力度颇大，单案最高奖励可达20万元。前述从业者向记者表示，转型阵痛期下，会有更多企业向内调 整。 利润 ...

Overview - The global infertility rate is rising, leading to increased demand for assisted reproductive technology (ART) and driving the growth of the reproductive medical equipment market in China [1][13] - Changing fertility concepts, delayed childbearing age, and heightened awareness of reproductive health are expanding the market opportunities for reproductive medical devices [1][13] - The aging population and government encouragement for having more children are further stimulating demand for reproductive medical equipment [1][13] - The market size of China's reproductive medical equipment industry is projected to reach 9.69 billion yuan in 2024, with a year-on-year growth of 9.86% [1][13] Market Policies - The Chinese government has issued various policies to support the development of the medical device industry, including reproductive medical equipment [7] - Policies aim to strengthen management, enhance innovation, and promote high-quality development in the medical device sector [7] Industry Chain - The upstream of the reproductive medical equipment industry includes suppliers of chemical materials, biological medical materials, electronic components, and software systems [9] - The midstream involves the research, design, and production of reproductive medical devices [9] - The downstream consists of public hospitals, private reproductive centers, and patients who benefit from these medical devices [9][11] Competitive Landscape - Historically, imported brands dominated the high-end market of reproductive medical devices in China, but domestic companies are increasingly closing the technology gap [13][14] - By 2024, domestic reproductive medical devices are expected to account for 55.11% of the market share, indicating a shift from reliance on imports to domestic alternatives [13][14] Company Analysis - Suzhou Beikang Medical Co., Ltd. focuses on reproductive health product development and achieved a revenue of 299 million yuan in 2024, with a gross profit margin of 45.54% [14][15] - Awei Technology Co., Ltd. specializes in clinical medical testing equipment and achieved a revenue of 203 million yuan in 2024, with 97.74% coming from medical device sales [15] Development Trends - Future advancements in reproductive medical devices will focus on greater intelligence, automation, and personalization, driven by technologies like gene editing and artificial intelligence [15][16] - Domestic companies are expected to continue improving their technological capabilities and market recognition, leading to an accelerated process of domestic substitution in the market [15][16]

Group 1 - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 3.40 yuan per share (tax included) [2] - The record date for the dividend is set for September 10, 2025, with the ex-dividend date and payment date both on September 11, 2025 [2]

证券代码：688399 证券简称：硕世生物 公告编号：2025-032 江苏硕世生物科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：否 三、 相关日期 ? 每股分配比例 每股现金红利3.40元 ? 相关日期 股权登记日 除权（息）日 现金红利发放日 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 8 月 27 日的2025年第一次临时股东大会审 议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 东。 本次利润分配以方案实施前的公司总股本83,871,721股为基数，每股派发现 金红利3.40元（含税），共计派发现金红利285,163,851.40元。 股权登记日 除权（息）日 现金红利发放日 四、 分配实施办法 除公司自行发放对象外，公司其余无限售条件流通股的红利委托中国结算上 海分公司通过其资金清算系统向股权登记日上海证 ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-032 江苏硕世生物科技股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 东。 每股现金红利3.40元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/10 | 2025/9/11 | 2025/9/11 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 8 月 27 日的2025年第一次临时股东大会审 议通过。 是否涉及差异化分红送转：否 每股分配比例 3. 分配方案： 本次利润分配以方案实施前的公司总股本83,871,721股为基数，每股派发现 金红利3.40元（含税），共计派发现金红利 ...